Myopia could be mistaken for glaucoma in some

Article

A study published in the March issue of Ophthalmology, has found that many young and middle-aged people of Chinese ancestry who are told they have glaucoma may actually be misdiagnosed. These patients who do not show disease progression may, in fact, have glaucoma-like symptoms caused by myopia.

A study published in the March issue of Ophthalmology, has found that many young and middle-aged people of Chinese ancestry who are told they have glaucoma may actually be misdiagnosed. These patients who do not show disease progression may, in fact, have glaucoma-like symptoms caused by myopia.

Amish Doshi, MD and colleagues from Stanford University, USA, observed more than 100 cases and fully reviewed the medical records of 16 Chinese men (average age 38.9 years) who had ocular symptoms suggestive of glaucoma. Average intraocular pressures (IOPs) ranged from 13.5 mmHg to 17.9 mmHg and 56.3% of subjects were using IOP-lowering medications.

Over a seven-year follow-up period, none of the subjects showed either progressive optic nerve cupping or visual field loss, regardless of whether they used anti-glaucoma medications.

Researchers discovered that 43.8% of eyes had myopia greater than 6 D, 75% of eyes had tilted discs and 81.3% of optic nerves had peripapillary atrophy. Cup-to-disc ratios averaged 0.56. The most common visual field defect was an arcuate defect, found in 31.3% of subjects.

The researchers believe that progressive myopia may have caused a strain gradient that affected susceptible axons in the preliminary optic nerve head tissue, leading to vision loss. The condition is now being studied in a larger population sample.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.